Navigation Links
VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
Date:12/29/2009

MOUNTAIN VIEW, Calif., Dec. 29 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS), a biopharmaceutical company developing innovative, next-generation medical therapies to address unmet needs in obesity, diabetes and sexual health, announced today that a New Drug Application (NDA) has been submitted to the U.S. Food and Drug Administration (FDA) seeking approval of Qnexa, its investigational drug for the treatment of obesity, including weight loss and maintenance of weight loss, in patients who are obese or overweight with co-morbidities such as hypertension, type 2 diabetes, dyslipidemia or central adiposity.

The NDA submission follows the successful completion of the phase 3 program for Qnexa, including the recently announced results from the two pivotal, year-long phase 3 studies, EQUIP and CONQUER. In these trials, patients treated with all three doses of Qnexa achieved significant percent and categorical weight loss compared to placebo and met regulatory requirements for weight loss products as defined in the current FDA Guidance for Developing Products for Weight Management. Patients treated with Qnexa also had significant dose-related improvements in a variety of secondary endpoints including reductions in cardiovascular and metabolic risk factors.

"This NDA filing is a major milestone for VIVUS and the Qnexa program. The weight loss seen in all of the phase 3 trials supports our belief that, if approved, Qnexa could be an effective treatment for patients who are obese or overweight with co-morbidities," stated Leland F. Wilson, chief executive officer for VIVUS. "The weight loss of up to 14.7% (37 pounds) combined with significant improvements in weight-related medical conditions, such as hypertension, diabetes, and dyslipidemia, demonstrates the importance of treating obesity, which has become a major epidemic
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Results From Phase 3 EQUATE Trial of VIVUS Qnexa Highlighted at European Congress on Obesity
2. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
3. Data on VIVUS Qnexa to be Featured at European Association for the Study of Diabetes Annual Meeting
4. VIVUS Announces Promotion of Peter Tam to President
5. VIVUS to Present at Lazard Capital Markets Healthcare Conference
6. VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
7. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
8. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
9. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
10. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
11. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 22, 2014 Research and Markets ... Chinese Intravenous Catheter Industry Report 2014" report to ... Intravenous Catheter Industry Report 2014 is a professional and ... intravenous catheter industry with a focus on the Chinese ... the industry including definitions, classifications, applications and industry chain ...
(Date:8/22/2014)... Aug. 22, 2014  Mark Riccio, director of ... facility, is using the online crowd-funding platform Kickstarter ... imaging to researchers and would-be superheros everywhere: "for ... would YOU do if you had Superman,s X-ray ... and explorers everywhere, from elementary through high school ...
(Date:8/22/2014)... - SQI Diagnostics Inc. (TSX-V: SQD), a life ... and products for advanced microarray diagnostics, today announced ... Agreement to contract with a UK-based company to ... initial phase of this agreement, SQI will be ... one of the customer,s assays, operational on SQI,s ...
Breaking Medicine Technology:Global and Chinese Intravenous Catheter Industry Report 2014 2Cornell's X-ray Imaging Lab Director Uses Kickstarter Campaign to "Democratize" Advanced 3D Imaging 2SQI Diagnostics Contracted to Automate Pathogen Detection Assays 2SQI Diagnostics Contracted to Automate Pathogen Detection Assays 3
... Jan. 26, 2011 QPS, LLC, a leading full-service ... preclinical and clinical research and development, announced the acquisition ... a full service phase 1 CRO headquartered in Hyderabad, ... QPS is a global CRO supporting drug discovery and ...
... FORT WORTH, Texas, Jan. 26, 2011 Wound Management ... an emerging leader in advanced wound care solutions, announced ... provider, Secure eHealth will be included in a technology ... Conference February 21st-24th at the Orange County Convention Center ...
Cached Medicine Technology:QPS Expands Phase 1 and Bioanalytical Capability by Acquisition of Bioserve, India 2Wound Management Technologies Announces Secure eHealth Technology to be Included During HIMSS 2011 Interoperability Showcase 2Wound Management Technologies Announces Secure eHealth Technology to be Included During HIMSS 2011 Interoperability Showcase 3Wound Management Technologies Announces Secure eHealth Technology to be Included During HIMSS 2011 Interoperability Showcase 4
(Date:8/22/2014)... Indiana (PRWEB) August 22, 2014 The ... Toyota Indiana is on the grow again. ... 300 jobs by summer 2016 to boost production of ... will bring Toyota Indiana’s overall investment to $4 billion. ... North America while providing additional flexibility to adjust its ...
(Date:8/22/2014)... - A Penn Medicine team has found that ... reduce urinary tract infections in hospital patients with ... the alert was simplified, the rate of improvement ... whether their patients need urinary catheters in the ... the need for catheters that have not been ...
(Date:8/22/2014)... 22, 2014 (HealthDay News) -- Many Americans know little about ... possibility of an outbreak in the United States, a new ... are worried that there will be a major Ebola outbreak ... or an immediate family member will get sick with the ... Harvard School of Public Health poll. However, those opinions ...
(Date:8/22/2014)... Millennium Treatment Group, a drug ... recently launched a new website. Patients, parents, loved ... now find Millennium Treatment Group at http://www.millenniumtreatmentgroup.com ... at the beginning of July. Everything anyone would ... found on the website. There’s an About Us ...
(Date:8/22/2014)... 2014 Beat Eczema , Susan ... use natural methods to completely cure the eczema symptoms ... of Shane Michaels, prompting an investigative review. , ... skin, it can still be extremely debilitating and life-altering ... intense itching and pain that it causes on the ...
Breaking Medicine News(10 mins):Health News:Toyota Indiana Adding 300 Jobs to Build More Highlanders 2Health News:Penn study: Electronic alerts significantly reduce catheter-associated urinary tract infections 2Health News:Penn study: Electronic alerts significantly reduce catheter-associated urinary tract infections 3Health News:Many Americans Harbor Unfounded Fears About Ebola Outbreak: Survey 2Health News:Millennium Treatment Group Has a New Website 2Health News:Beat Eczema: Review Exposes Susan Clark’s Guide to Curing Eczema Naturally 2
... to begin restocking poultry farms that had been struck by ... in Burma have reported that farms affected by bird flu ... of birds and poultry feed, while keeping such areas under ... bird flu outbreak since April 6th.The first outbreak of the ...
... warning to the public that they could end up buying ... , , Drugs such as Viagra, Tamiflu, Prozac and Valium, ... to be fakes or contaminated. ,Nigel Strick, the ... a prescription can turn out to be extremely ...
... High Court ruled on Thursday in favour of a ... Westville prisons department// must immediately remove restrictions on free ... ,The case was brought on behalf of ... prisoners and the Treatment Action Campaign stated that the ...
... The reason the MRSA superbug is so prevalent is because ... published in the British Journal of Nursing//. The study found ... in excess of the permissible 82 percent bed occupancy rates ... ,Researchers from the University of Ulster said that the ...
... burgers, fries and ice cream. Want a girl? Then go on ... according to John Roche, a scientist at New Zealand's dairy research ... mammal will hold true across the board," he said. ... 18-year research project from 1986 to 2004. ,They found ...
... country today called for mass screening to identify people prone ... national stroke prevention policy. // ,On the eve ... popular myths about strokes -- widely and wrongly believed to ... ,"Unlike heart attacks, people know very little about strokes. ...
Cached Medicine News:Health News:Does Weight of the Mother Determine the Sex of the Baby? 2
... been selling replacement bulbs on ... we are extremely proud of ... out our catalog of replacement ... light bulbs specials. ,Check ...
... With the Symphony family of Pacemakers, ... the market. Symphony, lighter than a passport, ... follow-up, using new technologies, and delivering powerful ... indicated for dual-chamber and atrial tracking modes ...
With the Symphony family of Pacemakers, Ela presents the most advanced technology on the market. Symphony, lighter than a passport, will take your patients further, offering fast follow-up, using new...
... precise and accurate Measurements! ,Patients are impressed ... examination when they see the doctor is ... - after only 5 minutes of proper ... proficient in the operation of this instrument ...
Medicine Products: